Investigation of Eluxadoline for Diabetic Diarrhea
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04313088 |
|
Recruitment Status :
Not yet recruiting
First Posted : March 18, 2020
Last Update Posted : March 3, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Diabetes is a chronic disease that affects a large part of the United States population. The majority of patients with diabetes will experience gastrointestinal symptoms. One of the most troublesome gastrointestinal symptoms that diabetes can cause is diarrhea, otherwise known as "Diabetic Diarrhea." This occurs because diabetes does damage to nerves that control the gut and prevent it from functioning normally. Currently, there are only several medications used to treat the symptoms of Diabetic Diarrhea, but many of these medications have serious side effects or do not work well.
We are investigating the drug eluxadoline for the treatment of Diabetic Diarrhea. Eluxadoline is a gut-specific medication that is FDA approved to treat diarrhea related to irritable bowel syndrome (IBS-D). Our hypothesis is eluxadoline will safely and successfully reduce diarrhea symptoms (number of stools and less liquid stools) and improve the quality of life in patients with Diabetic Diarrhea when compared with placebo. Each patient with Diabetic Diarrhea who participates will take both eluxadoline and a placebo drug at separate times over a period of several months as part of a crossover study design. While on each medication, eluxadoline or placebo, the participants will keep a diary of symptoms and will be followed by the medical team through a combination of office visits and questionnaires. There will be five planned office visits and intermittent phone calls (questionnaires, surveys) over the 140-day study period. Participants will not be permitted to use any other anti-diarrhea medication during the study period and will continue on medication for management of their diabetes.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetic Diarrhea Diabetes Diarrhea | Drug: Eluxadoline 100 mg | Phase 2 Phase 3 |
Over 30 million Americans have been diagnosed with diabetes and the related complications account for the 7th most common cause of death in the United States. Within the gastrointestinal system, diabetic enteropathy can manifest in a variety of ways of which diarrhea (DD) may be amongst the most debilitating. The prevalence of DD has been estimated to approach 20%. Autonomic neuropathy, loss of nitrergic neurons and loss of stimulation of alpha adrenergic neurons have all been postulated to have an effect on gut motility and water reabsorption. New research may indicate that chronic hyperglycemia damages Interstitial Cells of Cajal and other enteric nerves through oxidative stress to cause symptoms. Other areas of emerging research have explored the role of enteric hormones, smooth muscle cell abnormalities, inflammatory mediators, enteric glial cells, and the patients' microbiome as factors in the pathogenesis of DD Globally, symptoms of DD are inversely correlated with glycemic control. DD is a diagnosis of exclusion and its associated voluminous, watery stools are often unresponsive to conventional therapy.
Eluxadoline has emerged as an FDA approved drug for the treatment of IBS-D. It is an agonist of mu and kappa opioid receptors while also an antagonist at delta receptors in the gut. Through these mechanisms, eluxadoline acts to slow peristalsis while at the same time prevents constipation and provides pain relief to patients with IBS-D. Given its success in the treatment of IBS-D, we hypothesize that eluxadoline will safely bring significant symptom relief and improve quality of life for patients with DD.
Our study is a double blind, placebo controlled cross over design to investigate the safety and effectiveness of eluxadoline in relieving the symptoms of DD. Diabetic patients over the age of 18 with diarrhea for which an alternative underlying etiology has not been identified will be eligible to participate in a pre-randomization phase lasting four weeks to document baseline symptoms. At the conclusion of the pre-randomization period, patients will be randomized to either Experimental Group A or Experimental Group B. Randomization will be performed by a statistician and only the Temple Pharmacist will be aware of the group assignment to distribute study drug or placebo. Participants will receive either eluxadoline 100mg by mouth twice daily or matching placebo for 42 days, complete a washout period of 28 days when neither placebo or eluxadoline will be given, and then continue on by taking either eluxadoline or placebo for an additional 42 days based on which experimental group they have been assigned. Throughout the study period, patients will keep a daily stool diary, participate in questionnaires administered by a study coordinator and have pre-determined follow up office visits with study physicians.
The primary endpoint compared between eluxadoline and placebo will be proportion of days in which all bowel movements for that day have a consistency on the Bristol Stool Scale <5. Secondary endpoints will be improvement on the subject's Likert scores for global satisfaction, score on the Diabetes-39 and Facit-D questionnaires as well as proportion of days with fecal incontinence and nights with nocturnal diarrhea. We hypothesize that compared to placebo, eluxadoline will significantly improve the primary and secondary endpoints described above.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 24 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Intervention Model Description: | Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily (BID) or matching placebo. Participants will take assigned medication or placebo as prescribed for 42 days. A washout phase will take place on days 43-70. On days 71-112, participants will crossover and take either eluxadoline 100mg BID or matching placebo based on their previously assigned group. Throughout the study, weekly phone calls with a study coordinator will take place and participants will keep a daily stool diary. Office visits with a physician will take place at the beginning of the pre-randomization phase and at Day 0, 42, 70 and 112 of the study phase. Participants will refrain from use of all additional anti-diarrheal medication during the entirety of the study. |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | Randomization assignments will be handled by the statistician by means of a random number generator and assignments will be kept in opaque envelopes. The randomization scheme will be passed to the Temple Pharmacist. Based on the number, the Temple Pharmacist will dispense directly to the patient either drug or placebo in a labeled, child proof, pill bottle in a manner that does not disclose which group the patient is assigned. The Temple Pharmacist that is not a participant in the study will be responsible for dispensing study medication and will keep a secured log with the identity of that which is dispensed in case un-blinding becomes necessary. |
| Primary Purpose: | Treatment |
| Official Title: | Double Blind, Placebo Controlled, Cross Over Study to Investigate the Effectiveness and Safety of Eluxadoline in the Treatment of Diabetic Diarrhea |
| Estimated Study Start Date : | July 1, 2022 |
| Estimated Primary Completion Date : | December 2023 |
| Estimated Study Completion Date : | December 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental Group A
All eligible patients will receive both eluxadoline and placebo, however each patient will be randomized to the order in which this happens. Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily then matching placebo or placebo then eluxadoline 100mg twice daily. Participants in Group A will take eluxadoline 100mg by mouth twice for 42 days. A washout phase will take place on days 43-70 where no study drug or placebo will be administered. On days 71-112, participants will crossover and take matching placebo by mouth twice daily. Each participant in Group A will take 42 days of eluxadoline 100mg twice daily followed by 42 days of placebo over the course the study.
|
Drug: Eluxadoline 100 mg
Eluxadoline 100mg by mouth twice daily with food
Other Name: Viberzi |
|
Experimental Group B
All eligible patients will receive both eluxadoline and placebo, however each patient will be randomized to the order in which this happens. Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily then matching placebo or placebo then eluxadoline 100mg twice daily. Participants in Group B will take placebo by mouth twice daily for 42 days. A washout phase will take place on days 43-70 where no study drug or placebo will be administered. On days 71-112, participants will crossover and take eluxadoline 100mg by mouth twice daily. Each participant in Group B will take 42 days of placebo followed by 42 days of eluxadoline 100mg twice daily over the course the study.
|
Drug: Eluxadoline 100 mg
Eluxadoline 100mg by mouth twice daily with food
Other Name: Viberzi |
- Proportion of days with improved bowel movements [ Time Frame: 140 days ]
Proportion of days in which all recorded bowel movements for that day have a consistency on the Bristol Stool Scale of < 5.
Scale:
Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (easy to pass) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces, entirely liquid
- Likert score for global satisfaction [ Time Frame: 140 days ]
> 1 point improvement in the subject's Likert scores for global satisfaction with treatment
Scale:
High score means higher satisfaction
- - Strongly disagree
- - Disagree
- - Somewhat disagree
- - Neither agree nor disagree
- - Somewhat agree
- - Agree
- - Strongly agree
- Diabetes quality of life [ Time Frame: 140 days ]
Score on the Diabetes-39 (DM QoL questionnaire)
Scale:
1 - 7, with 1 being "not affected at all" and 7 being "extremely affected"
- Diarrhea quality of life [ Time Frame: 140 days ]
Score on the Facit-D (v. 4.0) - QoL questionnaire specific for diarrhea
Scale:
0 - Not at all
- - A little bit
- - Somewhat
- - Quite a bit
- - Very much
- Fecal incontinence [ Time Frame: 140 days ]Proportion of days with fecal incontinence
- Nocturnal diarrhea [ Time Frame: 140 days ]Proportion of days with nocturnal diarrhea
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years
- Documented diabetes mellitus (DM) Type I or DM Type II - must be on medical therapy
- ≥ 3 bowel movements per day with Bristol type 6 or 7 stools at least 4 days per week for > 6 months. They must continue to meet these criteria during the 4 week pre-randomization phase.
- Normal sigmoidoscopy or colonoscopy with biopsies negative for microscopic colitis
- Negative work up for Clostridium difficile
- Negative work up for Celiac Disease either by assessment of serum tissue transglutaminase Immunoglobulin A (IgA) or by small bowel biopsy
- Normal fecal elastase and fecal calprotectin levels
- Normal thryoid stimulating hormone (TSH) level
Exclusion Criteria:
- Subjects who, in the estimation of the investigator, have drug-induced diarrhea
- Subjects unwilling to stop anti-diarrheal medications during the study
- Pregnancy or nursing mothers
- History of Cholecystectomy or Sphincter of Oddi Dysfunction
- Patients unable to undergo sigmoidoscopy or colonoscopy
- Patients with a history of inflammatory bowel disease (IBD)
- Prior history of pancreatitis
- Patients with hepatic impairment
- Patients who consume ≥ 3 alcoholic beverages per day
- Patients on oral opioids, who abuse illicit opioids, or have had a history of opioid abuse
- Patients on OATP1B1 Inhibitors (Rifampicin, Clarithromycin, Erythromycin, Cyclosporine, Gemfibrozil)
- Patients for whom inclusion in the study would be dangerous
- Subjects unable to consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04313088
| Contact: Zachary Reichenbach, MD,PhD | 215-707-9900 | zachary.reichenbach@tuhs.temple.edu | |
| Contact: Frank Friedenberg, MD | 215-707-9900 | frank.friedenberg@tuhs.temple.edu |
| United States, Pennsylvania | |
| Temple University Hospital | |
| Philadelphia, Pennsylvania, United States, 19140 | |
| Contact: Zachary Reichenbach, MD, PhD 215-707-9900 zachary.reichenbach@tuhs.temple.edu | |
| Contact: Gregory Piech, MD, MPH 215-707-9900 gregory.piech@tuhs.temple.eud | |
| Principal Investigator: Zachary Reichenbach, MD,PhD | |
| Principal Investigator: | Zachary Reichenbach, MD,PhD | Lewis Katz School of Medicine at Temple University |
| Responsible Party: | Temple University |
| ClinicalTrials.gov Identifier: | NCT04313088 |
| Other Study ID Numbers: |
26347 |
| First Posted: | March 18, 2020 Key Record Dates |
| Last Update Posted: | March 3, 2022 |
| Last Verified: | February 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
eluxadoline Viberzi |
|
Diarrhea Signs and Symptoms, Digestive Eluxadoline Gastrointestinal Agents |